Daniel M. Skovronsky, MD, PhD, is Senior Vice President, Clinical and Product Development, Eli Lilly and Company, with responsibility for developing the Lilly pipeline of molecules and speeding innovative medicines to patients. Prior to this role he served as Vice President, Tailored Therapeutics. Dr. Skovronsky also serves as Chairman of Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company).
Dr. Skovronsky joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals. Previously, Dr. Skovronsky served as CEO of Avid, which he founded in late 2004. At Avid, Skovronsky led the discovery, development, and FDA approval of Amyvid®, the first diagnostic agent for brain imaging of beta-amyloid plaques in patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline.
Dr. Skovronsky trained as a resident in pathology and completed a fellowship in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biophysics and biochemistry at Yale University.